Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E–Mutated Colorectal CancerScott Kopetz, Josep Tabernero, Neeltje Steeghs et al.|New England Journal of Medicine|2019Cited by 1.5k
Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: incidence, course and managementHelen Gogas, Caroline Robert, Keith T. Flaherty et al.|European Journal of Cancer|2019Cited by 81
Update on overall survival in COLUMBUS: A randomized phase III trial of encorafenib (ENCO) plus binimetinib (BINI) versus vemurafenib (VEM) or ENCO in patients with <i>BRAF</i> V600-mutant melanoma.Helen Gogas, Reinhard Dummer, Paolo A. Ascierto et al.|Journal of Clinical Oncology|2020Cited by 23
Quality of life in patients with BRAF-mutant melanoma receiving the combination encorafenib plus binimetinib: Results from a multicentre, open-label, randomised, phase III study (COLUMBUS)Helen Gogas, Keith T. Flaherty, Reinhard Dummer et al.|European Journal of Cancer|2021Cited by 15
Adverse events of special interest in the phase 3 COLUMBUS study.Helen Gogas, Keith T. Flaherty, Reinhard Dummer et al.|Journal of Clinical Oncology|2018Cited by 3